No Data
Hong Kong stock concept tracking | The end of medical insurance negotiations is very encouraging for innovative drugs to be included in medical insurance at reasonable prices (with concept stocks)
The on-site negotiation and bidding stages for the adjustment of the national medical insurance pharmaceutical catalog in 2024 officially ended recently.
Is it the most 'rolled up' in history? The tenth batch of national procurement pharmaceutical catalog is officially announced, with up to 31 companies competing for a single variety.
①This afternoon, the National Pharmaceutical Centralized Procurement Office officially announced the tenth batch of national procurement pharmaceutical catalog, with a total of 263 specifications and 62 varieties; ②Many industry insiders believe that the tenth batch of national procurement will be the largest and most competitive national procurement in history.
luye pharma (02186) has completed the issuance of 0.1 billion US dollars convertible bonds.
luye pharma (02186) announced that the company issued $0.1 billion at a 5.85% interest rate convertible bond due in 2025...
Luye Pharma Group Files for Singapore Listing of $100 Million Bonds Due 2025
Zheshang Securities: Continuous realization of technological innovation upgrades driving the continuous improvement of performance expectations for innovative drugs and industry chains.
As the innovative drugs industry chain enters the commercialization realization period driven purely by incremental growth, the scarcity of incremental prosperity in the pharmaceutical sector continues to rise, international competitiveness continues to improve, and there is still room for upward valuation.
Hong Kong healthcare stocks receive attention from investors again, with Trifolium Biotech surging nearly 15%.
1. What is the impact of medical insurance negotiations on pharmaceutical stocks? 2. What are the reasons for the rise of Clover Biopharmaceuticals and Imin Ankang?
No Data
No Data